JPH06227996A - Medicine for control of body weight - Google Patents
Medicine for control of body weightInfo
- Publication number
- JPH06227996A JPH06227996A JP5012860A JP1286093A JPH06227996A JP H06227996 A JPH06227996 A JP H06227996A JP 5012860 A JP5012860 A JP 5012860A JP 1286093 A JP1286093 A JP 1286093A JP H06227996 A JPH06227996 A JP H06227996A
- Authority
- JP
- Japan
- Prior art keywords
- oolong tea
- body weight
- dried
- fiber
- saponin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000037396 body weight Effects 0.000 title claims abstract description 13
- 239000003814 drug Substances 0.000 title abstract description 4
- 229940079593 drug Drugs 0.000 title description 2
- 235000006468 Thea sinensis Nutrition 0.000 claims abstract description 38
- 235000020333 oolong tea Nutrition 0.000 claims abstract description 38
- 229930182490 saponin Natural products 0.000 claims abstract description 19
- 150000007949 saponins Chemical class 0.000 claims abstract description 19
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract description 18
- 239000000835 fiber Substances 0.000 claims abstract description 14
- 230000000694 effects Effects 0.000 abstract description 10
- 208000008589 Obesity Diseases 0.000 abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 5
- 239000004575 stone Substances 0.000 abstract description 4
- 239000000706 filtrate Substances 0.000 abstract description 3
- 235000004280 healthy diet Nutrition 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 210000003462 vein Anatomy 0.000 abstract description 3
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 abstract 2
- 239000000463 material Substances 0.000 abstract 2
- 235000009643 reducing diet Nutrition 0.000 abstract 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 229920001100 Polydextrose Polymers 0.000 abstract 1
- 229930006000 Sucrose Natural products 0.000 abstract 1
- 239000001913 cellulose Substances 0.000 abstract 1
- 229920002678 cellulose Polymers 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 239000001259 polydextrose Substances 0.000 abstract 1
- 229940035035 polydextrose Drugs 0.000 abstract 1
- 235000013856 polydextrose Nutrition 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000011369 resultant mixture Substances 0.000 abstract 1
- 239000005720 sucrose Substances 0.000 abstract 1
- -1 sucrose fatty acid ester Chemical class 0.000 abstract 1
- 235000017709 saponins Nutrition 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 10
- 238000004260 weight control Methods 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 5
- 235000020824 obesity Nutrition 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000012086 standard solution Substances 0.000 description 3
- 229920001864 tannin Polymers 0.000 description 3
- 235000018553 tannin Nutrition 0.000 description 3
- 239000001648 tannin Substances 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- XMVONEAAOPAGAO-UHFFFAOYSA-N sodium tungstate Chemical compound [Na+].[Na+].[O-][W]([O-])(=O)=O XMVONEAAOPAGAO-UHFFFAOYSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は天然物からの抽出成分を
配合した安全性の高い、肥満症の予防及び治療に有用な
体重抑制剤に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a highly safe weight control agent containing a component extracted from a natural product, which is useful for the prevention and treatment of obesity.
【０００２】[0002]
【従来の技術】肥満症は脂肪組織とくに皮下脂肪組織に
中性脂肪が異常に蓄積した結果、体重が骨格系あるいは
生理機能の限界を超えて増加した状態をいうが、肥満症
の状態まで行かなくとも体重が標準体重の２０％以上の
人はそうでない人に比較して糖尿病、動脈硬化症、脂肪
肝、高血圧症等を起こしやすいといわれている。また、
肥満は健康上の観点からだけでなく、美容上、さらには
服飾品等の経済上の観点からも予防又は治療すべきであ
る。2. Description of the Related Art Obesity is a condition in which body weight is increased beyond the limits of skeletal system or physiological function as a result of abnormal accumulation of neutral fat in adipose tissue, especially subcutaneous adipose tissue. It is said that a person who weighs 20% or more of the standard weight is more likely to have diabetes, arteriosclerosis, fatty liver, hypertension, etc. than a person who does not have a standard weight. Also,
Obesity should be prevented or treated not only from a health point of view, but also from a cosmetic point of view, and also from an economic point of view of clothing and the like.
【０００３】かかる肥満防止又は治療の手段としては食
事制限及び運動が基本と考えられるが、これらは継続性
等の点で困難であり、薬剤による体重抑制が種々提案さ
れている。例えば食物繊維、プロテイン、パフィアエキ
ス、グルコマンナン、低カロリー甘味料等である。As a means for preventing or treating obesity, dietary restriction and exercise are considered to be basic, but these are difficult in terms of continuity and the like, and various weight reductions by drugs have been proposed. For example, dietary fiber, protein, paffia extract, glucomannan, low-calorie sweetener and the like.
【０００４】[0004]
【発明が解決しようとする課題】しかしながら、これら
従来の体重抑制剤はいずれも効果が充分でない、安全性
が低い等の問題があった。従って、本発明の目的は体重
抑制効果及び安全性の高い体重抑制剤を提供することに
ある。However, all of these conventional weight-suppressing agents have problems such as insufficient effect and low safety. Therefore, an object of the present invention is to provide a body weight inhibitor having a high body weight inhibitory effect and safety.
【０００５】[0005]
【課題を解決するための手段】そこで本発明者らは中国
茶として知られているウーロン茶に着目し、その抽出成
分の作用について検討してきたところ、ウーロン茶サポ
ニンとウーロン茶ファイバーとを組み合せれば、これら
をそれぞれ単独で投与した場合に比べ優れた体重抑制作
用が得られることを見出し、本発明を完成するに至っ
た。[Means for Solving the Problems] Therefore, the present inventors have focused on oolong tea known as Chinese tea and have studied the action of its extractive ingredients. If oolong tea saponin and oolong tea fiber are combined, these It was found that an excellent body weight-suppressing action can be obtained as compared with the case where each of these is administered alone, and the present invention has been completed.
【０００６】すなわち、本発明はウーロン茶サポニン及
びウーロン茶ファイバーを含有する体重抑制剤を提供す
るものである。That is, the present invention provides a weight control agent containing oolong tea saponin and oolong tea fiber.
【０００７】本発明の体重抑制剤に配合されるウーロン
茶サポニン及びウーロン茶ファイバーはウーロン茶乾燥
葉より常法に従って製造することができる。ウーロン茶
サポニンは、例えばウーロン茶乾燥葉を６０〜８０℃で
３０〜６０分熱湯抽出し、固形物を除去し、濾液を濃縮
し、凍結乾燥することにより得られる。一方、ウーロン
茶ファイバーは、ウーロン茶乾燥葉より葉脈を除去して
葉部を粉砕し、殺菌処理することにより得られる。この
ようにして得られるウーロン茶サポニン及びウーロン茶
ファイバーは純品である必要はなく、それぞれ３０％以
上、特に３０〜６０％の含有量があればよい。The oolong tea saponin and oolong tea fiber to be incorporated in the body weight suppressor of the present invention can be produced from oolong tea dried leaves according to a conventional method. The oolong tea saponin is obtained, for example, by extracting dried oolong tea leaves in hot water at 60 to 80 ° C. for 30 to 60 minutes to remove solids, concentrating the filtrate, and freeze-drying. On the other hand, oolong tea fibers are obtained by removing veins from dried oolong tea leaves, crushing the leaves, and sterilizing the leaves. The oolong tea saponins and oolong tea fibers thus obtained do not have to be pure products, and may have a content of 30% or more, particularly 30 to 60%.
【０００８】本発明の体重抑制剤へのウーロン茶サポニ
ン及びウーロン茶ファイバーの配合量は、とくに制限さ
れないが、重量比（固形分）でウーロン茶サポニン：ウ
ーロン茶ファイバー＝１：５０〜５０：１、特に１：２
０〜１：１が好ましい。The amount of oolong tea saponin and oolong tea fiber to be added to the weight control agent of the present invention is not particularly limited, but the weight ratio (solid content) of oolong tea saponin: oolong tea fiber = 1: 50 to 50: 1, particularly 1: Two
0 to 1: 1 is preferred.
【０００９】また、本発明の体重抑制剤には、前記必須
成分以外に、体重増加の原因とならない成分、例えば賦
形剤、結合剤、崩壊剤、滑沢剤、甘味料、着色料、着香
料等を添加することができる。In addition to the above-mentioned essential components, the weight-suppressing agent of the present invention also contains components that do not cause weight gain, such as excipients, binders, disintegrants, lubricants, sweeteners, coloring agents, and dressing agents. Fragrances and the like can be added.
【００１０】本発明の体重抑制剤の剤型は、特に限定さ
れないが粉末、顆粒、錠剤等が好ましい。これらの剤型
を調製するには、前記の成分を混合し常法により製剤化
すればよい。The dosage form of the weight control agent of the present invention is not particularly limited, but powders, granules, tablets and the like are preferable. In order to prepare these dosage forms, the above-mentioned components may be mixed and formulated by a conventional method.
【００１１】本発明の体重抑制剤の投与量（摂取量）
は、体重、性別等によって異なるが、ウーロン茶サポニ
ン及びウーロン茶ファイバーの合計量として、成人１日
当り０．５〜１０ｇとするのが好ましい。また、投与
（摂取）方法としては、１日２〜３回に分けて経口的に
投与するのが望ましい。Dosage (intake) of the body weight suppressor of the present invention
Varies depending on body weight, sex, etc., but the total amount of oolong tea saponin and oolong tea fiber is preferably 0.5 to 10 g per day for an adult. In addition, it is desirable that the administration (ingestion) method be orally administered in 2 to 3 divided doses per day.
【００１２】[0012]
【実施例】次に実施例を挙げて本発明をさらに詳細に説
明するが、本発明はこれら実施例に限定されるものでは
ない。The present invention will be described in more detail with reference to examples, but the present invention is not limited to these examples.
【００１３】参考例１（ウーロン茶サポニンの製造） ウーロン茶乾燥葉５００kgに６０〜８０℃の湯を３００
ｌ加え、３０〜６０分間同温度に維持した後、８０〜１
５０メッシュの振動濾過器で濾過した。濾液をさらに濾
布を用いて濾過した後、加温真空濃縮し、凍結乾燥し
た。得られた凍結乾燥品の成分を下記の方法で分析した
結果、粗サポニンとして４０．７％含有していた。Reference Example 1 (Production of oolong tea saponin) 500 kg of dried oolong tea leaves and hot water at 60-80 ° C.
l, and after maintaining the same temperature for 30 to 60 minutes, 80 to 1
It was filtered with a 50 mesh vibrating filter. The filtrate was further filtered using a filter cloth, concentrated under vacuum with heating, and lyophilized. As a result of analyzing the components of the obtained freeze-dried product by the following method, 40.7% of crude saponin was contained.
【００１４】（サポニン定量法） （１）試料及びタンニン酸標準液（１０％）を適量１０
０mlのメスフラスコにとり、約９０mlの水を加え、次に
炭酸ナトリウム飽和溶液５mlを加え、次にＦｏｌｉｎ
Ｄｅｎｉｓ試薬〔水７５mlにタングステン酸ナトリウム
１０ｇと、リンモリブデン酸２ｇ及びリン酸５．０mlを
加え、冷却器をつけ２時間還流し、冷後１００mlとった
液〕３．０mlを加えた後、全量を１００mlとする。約１
時間後の吸光度（７００nm）を測定する。得られた吸光
度より、下記の式に従い、タンニン含量を求める。(Saponin quantitative method) (1) An appropriate amount of a sample and a tannic acid standard solution (10%) were used.
In a 0 ml volumetric flask, add about 90 ml of water, then 5 ml of saturated sodium carbonate solution, then Folin.
Denis reagent [sodium tungstate 10 g, phosphomolybdic acid 2 g and phosphoric acid 5.0 ml in 75 ml of water were added, and a condenser was added and refluxed for 2 hours, then cooled to 100 ml] To 100 ml. About 1
The absorbance (700 nm) after the lapse of time is measured. The tannin content is determined from the obtained absorbance according to the following formula.
【００１５】[0015]
【数１】 [Equation 1]
【００１６】Ａ：試料溶液の吸光度 ＡS：標準溶液の吸光度 ＡO：空試験溶液の吸光度 Ｂ：試料量 Ｓ：標準液濃度 （２）一方、ｎ−ブタノール抽出法により求めたサポニ
ンとタンニン合計量から上記（１）のタンニン量を引い
て、サポニン含量を求める。A: Absorbance of sample solution A S : Absorbance of standard solution A O : Absorbance of blank test solution B: Sample amount S: Concentration of standard solution (2) On the other hand, sum of saponin and tannin determined by n-butanol extraction method The amount of tannin in (1) above is subtracted from the amount to determine the saponin content.
【００１７】参考例２（ウーロン茶ファイバーの製造） ウーロン茶乾燥葉より葉脈部分を除去し、石うすを用い
て粉砕し、１５０〜２００メッシュのふるいで篩別し、
微粉末を得、さらに石うすで粉砕し、７０〜８０℃で６
０〜１２０分乾燥殺菌した。得られた粉末について成分
を分析した結果を表１に示す。Reference Example 2 (Production of Oolong Tea Fiber) A vein portion was removed from dried leaves of oolong tea, crushed with stone thin powder, and sieved with a 150 to 200 mesh sieve,
Fine powder was obtained, further crushed with stone dull,
It was dried and sterilized for 0 to 120 minutes. The results of analyzing the components of the obtained powder are shown in Table 1.
【００１８】[0018]
【表１】 [Table 1]
【００１９】＊１：Ｏ．Ａ．Ｔ．Ｓｏｕｔｈｇａｔｅら
の方法〔Ｊ．Ｓｃｉ．ＦｏｏｄＡｇｒｉｃ．，２０，３
３１（１９６９）〕に準じて試験。 ＊２：フェノール硫酸法にて測定〔ぶどう糖換算〕。 ＊３：ＤＤＴＣ−Ａｇ吸光光度法。 ＊４：硫化ナトリウム比色法。* 1: O. A. T. The method of Southgate et al. [J. Sci. FoodAgric. , 20, 3
31 (1969)]. * 2: Measured by the phenol-sulfuric acid method [converted into glucose]. * 3: DDTC-Ag absorptiometry. * 4: Sodium sulfide colorimetric method.
【００２０】実施例１ 表２に記載の処方で体重抑制剤を調製し、体重抑制効果
を試験した。Example 1 A weight control agent was prepared according to the formulation shown in Table 2 and tested for its weight control effect.
【００２１】[0021]
【表２】 [Table 2]
【００２２】（試験方法）表２のサンプルを４名のパネ
ラーに食前に５粒ずつ、１日３回、１０日間食べてもら
い体重の増減を測定した。なお、食事は１５００〜２０
００Kcalとした。 （結果）表３及び表４に示すように、ウーロン茶サポニ
ン又はウーロン茶ファイバー単味より両者の併用の場合
のほうが、体重抑制効果が優れていた。(Test method) The samples of Table 2 were eaten by 4 panelists, 5 tablets each before meal, 3 times a day for 10 days, and the increase / decrease in body weight was measured. In addition, meal is 1500-20
It was set to 00 Kcal. (Results) As shown in Tables 3 and 4, the combined use of the oolong tea saponin and the oolong tea fiber was superior to the oolong tea saponin or the oolong tea fiber alone.
【００２３】[0023]
【表３】 [Table 3]
【００２４】[0024]
【表４】 [Table 4]
【００２５】実施例２ 表５の処方の体重抑制剤を調製し、実施例１と同様の方
法で体重抑制効果を試験した。その結果を表６及び表７
に示す。Example 2 A weight control agent having the formulation shown in Table 5 was prepared, and the weight control effect was tested in the same manner as in Example 1. The results are shown in Tables 6 and 7.
Shown in.
【００２６】[0026]
【表５】 [Table 5]
【００２７】[0027]
【表６】 [Table 6]
【００２８】[0028]
【表７】 [Table 7]
【００２９】なお、パネラー５人の健康状態に何ら異常
は認められず、肌のつや食欲も良好であった。No abnormalities were observed in the health condition of the five panelists, and their skin had a good gloss and appetite.
【００３０】[0030]
【発明の効果】本発明の体重抑制剤を用いれば何ら副作
用を生ずることなく、優れた体重抑制効果が得られるの
で、肥満症の治療に、また健康的なダイエットに有用で
ある。EFFECTS OF THE INVENTION The weight-suppressing agent of the present invention provides an excellent weight-suppressing effect without causing any side effects, and is therefore useful for treating obesity and for a healthy diet.
Claims (1)
イバーを含有する体重抑制剤。1. A body weight suppressant containing oolong tea saponin and oolong tea fiber.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5012860A JPH06227996A (en) | 1993-01-28 | 1993-01-28 | Medicine for control of body weight |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5012860A JPH06227996A (en) | 1993-01-28 | 1993-01-28 | Medicine for control of body weight |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH06227996A true JPH06227996A (en) | 1994-08-16 |
Family
ID=11817171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5012860A Pending JPH06227996A (en) | 1993-01-28 | 1993-01-28 | Medicine for control of body weight |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH06227996A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998008527A1 (en) * | 1996-08-30 | 1998-03-05 | Zenyaku Kogyo Kabushiki Kaisha | Yacon/oolong blend tea |
| US6214349B1 (en) * | 1996-03-12 | 2001-04-10 | Nature's Sunshine Products, Inc. | Composition for limiting the assimilation of dietary fat and methods of making and using same |
| WO2005087025A1 (en) * | 2004-03-15 | 2005-09-22 | Bioferme Oy | Composition; use of a composition and a method for treating obesity |
| US7150889B2 (en) | 2000-01-18 | 2006-12-19 | Nagaoka Perfumery Co., Ltd. | Anti-obestic composition |
-
1993
- 1993-01-28 JP JP5012860A patent/JPH06227996A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6214349B1 (en) * | 1996-03-12 | 2001-04-10 | Nature's Sunshine Products, Inc. | Composition for limiting the assimilation of dietary fat and methods of making and using same |
| WO1998008527A1 (en) * | 1996-08-30 | 1998-03-05 | Zenyaku Kogyo Kabushiki Kaisha | Yacon/oolong blend tea |
| US7150889B2 (en) | 2000-01-18 | 2006-12-19 | Nagaoka Perfumery Co., Ltd. | Anti-obestic composition |
| US7687085B2 (en) | 2000-01-18 | 2010-03-30 | Nagaoka Perfumery Co., Ltd | Anti-obestic composition |
| WO2005087025A1 (en) * | 2004-03-15 | 2005-09-22 | Bioferme Oy | Composition; use of a composition and a method for treating obesity |
| AU2005220626B2 (en) * | 2004-03-15 | 2010-11-11 | Bioferme Oy | Composition; use of a composition and a method for treating obesity |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4693963B2 (en) | Estrogen-like agent, collagen production promoter, and fibroblast proliferating agent | |
| JP3095605B2 (en) | Health foods and beverages containing antioxidants and methods for producing antioxidants | |
| JPH09227398A (en) | Antiobesity agent | |
| WO2013100105A1 (en) | Maillard reaction inhibitor | |
| CN109589400B (en) | Composition with neuroprotective effect | |
| JP4495406B2 (en) | Sendangusa plant extract-containing composition | |
| KR20000023394A (en) | Enzymatic lysate of lavor and uses thereof | |
| JP6527715B2 (en) | Black ginger containing composition | |
| JP3650587B2 (en) | Functional food containing glycosphingolipid and method for producing the same | |
| JPH06227996A (en) | Medicine for control of body weight | |
| JP6844857B2 (en) | A skin moisturizing composition containing acacia bark-derived products | |
| JP2019147824A (en) | Kaempferia parviflora-containing compositions | |
| JPH0761953B2 (en) | Manufacturing method of immunity strengthening and constitution improving agent | |
| DE69431454T2 (en) | Amylase inhibitors | |
| JP6999907B2 (en) | Composition for promoting clock gene expression | |
| KR0179088B1 (en) | Diabetic prophylaxis and treatment composition containing Rhodiola saline extract | |
| ITMI20010644A1 (en) | COMPOSITION BASED ON A VEGETABLE COAGULATED PRODUCT COMPOSITE PROCESS FOR ITS MANUFACTURE AND ITS USES | |
| JPH0310609B2 (en) | ||
| DE69008050T2 (en) | A physiologically active substance, conventional from malt, and process for its production. | |
| JPH06239758A (en) | Complexion improving agent and composition containing the agent | |
| JP2001316279A (en) | Composition for fatigue recovery | |
| JPH08133959A (en) | Skin cosmetic | |
| TWI653989B (en) | a composition comprising an herbal extract obtained by processing oriental herbs | |
| KR101332531B1 (en) | Composition for preventing and/or treating itching containing component originating in the bark of tree belonging to the genus acacia | |
| JP2003212775A (en) | Physiologically active composition |